Development of a Hydroxyurea Decision Aid for Parents of Children with Sickle Cell Anemia

Lori E. Crosby; Ashley Walton; Lisa M. Shook; Russell E. Ware; Marsha Treadwell; Kay L. Saving; Maria Britto; James Peugh; Emily McTate; Suzette Oyeku; Cara Nwankwo; William B. Brinkman

doi:10.1097/MPH.0000000000001257

Development of a Hydroxyurea Decision Aid for Parents of Children with Sickle Cell Anemia

Lori E. Crosby, Ashley Walton, Lisa M. Shook, Russell E. Ware, Marsha Treadwell, Kay L. Saving, Maria Britto, James Peugh, Emily McTate, Suzette Oyeku, Cara Nwankwo, William B. Brinkman

Pediatrics

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

National evidence-based guidelines recommend offering hydroxyurea to patients with sickle cell anemia 9 months of age and older using shared decision making, but offer no strategies to aid implementation. We developed a hydroxyurea multicomponent decision aid via a needs assessment, clinic observations, and iterative feedback to address parent decision needs and promote a discussion between clinicians and parents. A total of 75 parents and 28 clinicians participated across all phases. The decision aid was rated as useful. Hydroxyurea knowledge improved and decisional conflict decreased supporting the potential for use to facilitate shared decision making in pediatric sickle cell anemia.

Original language	English (US)
Pages (from-to)	56-63
Number of pages	8
Journal	Journal of Pediatric Hematology/Oncology
Volume	41
Issue number	1
DOIs	https://doi.org/10.1097/MPH.0000000000001257
State	Published - Jan 1 2019

Keywords

decision aids
decision making
hydroxyurea
pediatric
treatment preference

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Hematology
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/MPH.0000000000001257

Cite this

@article{27c2a140fd8a42eb9396de514261cf1e,

title = "Development of a Hydroxyurea Decision Aid for Parents of Children with Sickle Cell Anemia",

abstract = "National evidence-based guidelines recommend offering hydroxyurea to patients with sickle cell anemia 9 months of age and older using shared decision making, but offer no strategies to aid implementation. We developed a hydroxyurea multicomponent decision aid via a needs assessment, clinic observations, and iterative feedback to address parent decision needs and promote a discussion between clinicians and parents. A total of 75 parents and 28 clinicians participated across all phases. The decision aid was rated as useful. Hydroxyurea knowledge improved and decisional conflict decreased supporting the potential for use to facilitate shared decision making in pediatric sickle cell anemia.",

keywords = "decision aids, decision making, hydroxyurea, pediatric, treatment preference",

author = "Crosby, {Lori E.} and Ashley Walton and Shook, {Lisa M.} and Ware, {Russell E.} and Marsha Treadwell and Saving, {Kay L.} and Maria Britto and James Peugh and Emily McTate and Suzette Oyeku and Cara Nwankwo and Brinkman, {William B.}",

note = "Funding Information: Supported in part by Agency for Healthcare Research and Quality{\textquoteright}s (AHRQ) Centers for Education and Research in Therapeutics (CERTs) Grant number: 1U19HS021114. This project was also supported by the Health Resources and Services Administration (HRSA) Sickle Cell Disease Treatment Demonstration Program grant number: U1EMC27863. The Hemoglobinopathy Learning Collaborative was supported by funding from the Health Resources and Services Administration (HRSA) Sickle Cell Disease Treatment Demonstration Program Sickle Cell Disease Treatment Demon-stration Program (HRSA Contract #HHSH25020100022C). The content is solely the responsibility of the authors and does not necessarily represent the official views of the AHRQ or HRSA. Publisher Copyright: {\textcopyright} 2018 Wolters Kluwer Health, Inc. All rights reserved.",

year = "2019",

month = jan,

day = "1",

doi = "10.1097/MPH.0000000000001257",

language = "English (US)",

volume = "41",

pages = "56--63",

journal = "Journal of Pediatric Hematology/Oncology",

issn = "1077-4114",

publisher = "Lippincott Williams and Wilkins",

number = "1",

}

TY - JOUR

T1 - Development of a Hydroxyurea Decision Aid for Parents of Children with Sickle Cell Anemia

AU - Crosby, Lori E.

AU - Walton, Ashley

AU - Shook, Lisa M.

AU - Ware, Russell E.

AU - Treadwell, Marsha

AU - Saving, Kay L.

AU - Britto, Maria

AU - Peugh, James

AU - McTate, Emily

AU - Oyeku, Suzette

AU - Nwankwo, Cara

AU - Brinkman, William B.

N1 - Funding Information: Supported in part by Agency for Healthcare Research and Quality’s (AHRQ) Centers for Education and Research in Therapeutics (CERTs) Grant number: 1U19HS021114. This project was also supported by the Health Resources and Services Administration (HRSA) Sickle Cell Disease Treatment Demonstration Program grant number: U1EMC27863. The Hemoglobinopathy Learning Collaborative was supported by funding from the Health Resources and Services Administration (HRSA) Sickle Cell Disease Treatment Demonstration Program Sickle Cell Disease Treatment Demon-stration Program (HRSA Contract #HHSH25020100022C). The content is solely the responsibility of the authors and does not necessarily represent the official views of the AHRQ or HRSA. Publisher Copyright: © 2018 Wolters Kluwer Health, Inc. All rights reserved.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - National evidence-based guidelines recommend offering hydroxyurea to patients with sickle cell anemia 9 months of age and older using shared decision making, but offer no strategies to aid implementation. We developed a hydroxyurea multicomponent decision aid via a needs assessment, clinic observations, and iterative feedback to address parent decision needs and promote a discussion between clinicians and parents. A total of 75 parents and 28 clinicians participated across all phases. The decision aid was rated as useful. Hydroxyurea knowledge improved and decisional conflict decreased supporting the potential for use to facilitate shared decision making in pediatric sickle cell anemia.

AB - National evidence-based guidelines recommend offering hydroxyurea to patients with sickle cell anemia 9 months of age and older using shared decision making, but offer no strategies to aid implementation. We developed a hydroxyurea multicomponent decision aid via a needs assessment, clinic observations, and iterative feedback to address parent decision needs and promote a discussion between clinicians and parents. A total of 75 parents and 28 clinicians participated across all phases. The decision aid was rated as useful. Hydroxyurea knowledge improved and decisional conflict decreased supporting the potential for use to facilitate shared decision making in pediatric sickle cell anemia.

KW - decision aids

KW - decision making

KW - hydroxyurea

KW - pediatric

KW - treatment preference

UR - http://www.scopus.com/inward/record.url?scp=85052827204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052827204&partnerID=8YFLogxK

U2 - 10.1097/MPH.0000000000001257

DO - 10.1097/MPH.0000000000001257

M3 - Article

C2 - 30044352

AN - SCOPUS:85052827204

SN - 1077-4114

VL - 41

SP - 56

EP - 63

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

IS - 1

ER -

Development of a Hydroxyurea Decision Aid for Parents of Children with Sickle Cell Anemia

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this